Four-week studies of oral hypoxia-inducible factor–prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia
L Holdstock, AM Meadowcroft, R Maier… - Journal of the …, 2016 - journals.lww.com
Hypoxia-inducible factor prolyl hydroxylase inhibitors stabilize levels of hypoxia-inducible
factor that upregulate transcription of multiple genes associated with the response to
hypoxia, including production of erythropoietin. We conducted two phase 2a studies to
explore the relationship between the dose of the hypoxia-inducible factor–prolyl hydroxylase
inhibitor GSK1278863 and hemoglobin response in patients with anemia of CKD (baseline
hemoglobin 8.5–11.0 g/dl) not undergoing dialysis and not receiving recombinant human …
factor that upregulate transcription of multiple genes associated with the response to
hypoxia, including production of erythropoietin. We conducted two phase 2a studies to
explore the relationship between the dose of the hypoxia-inducible factor–prolyl hydroxylase
inhibitor GSK1278863 and hemoglobin response in patients with anemia of CKD (baseline
hemoglobin 8.5–11.0 g/dl) not undergoing dialysis and not receiving recombinant human …